Figure S4. Box plot showing the distribution of TMB between those who had a partial response (PR) or stable disease (SD) to immunotherapy compared to patients who had primary progressive disease (PD). Box plots represent medians, interquartile ranges, and vertical lines extend to the highest and the lowest TMB values. TMB of individual patients are represented with dots. (DOCX 62 kb
Figure S4. Scatter plot demonstrating the correlation between infiltrating PD-1+ tumor-infiltrating ...
Figure S2. Disease control rates for PD-L1 positive (TPS >â1%) and negative tumors combined with c...
Figure S3. Scatter plots demonstrating the correlation between PD-L1 expression on tumor cells and t...
Figure S2. Box plot showing the distribution of TMB between the entire cohort of patients with SCLC ...
Figure S5. Kaplan-Meier analysis of overall survival (OS) calculated from the date of initial pathol...
Figure S6. Kaplan-Meier analysis of progression-free survival (PFS) to first-line chemotherapy in th...
Figure S3. Kaplan-Meier analysis of (A) progression-free survival (PFS) and (B) overall survival (OS...
Figure S1. Diagram of patients with SCLC who underwent successful next generation sequencing who eit...
Table S1. Samples (n=209) sorted within tumor type by PD-L1 rank (RNA-seq). Table S2. PD-L1 (CD274) ...
Figure S1. Comparison of CD8 levels in PD-L1 negative and positive groups. A & B: Comparison of CD8 ...
Table S1. Clinical characteristics. Table S2. RNA-seq gene function list. Table S3. Gene function an...
Table S1. Patientsâ clinical characteristics. Ten newly diagnosed lung cancer patients who were tr...
Figure S2. The consistency of mutation numbers, ITH and phylogenetic trees between panel sequencing ...
Figure S1. Methods, antibodies and validation that IIC-density does not correlate with patient clini...
Figure S1. The correlations of TMB value between panel sequencing and WES in published databases. Fi...
Figure S4. Scatter plot demonstrating the correlation between infiltrating PD-1+ tumor-infiltrating ...
Figure S2. Disease control rates for PD-L1 positive (TPS >â1%) and negative tumors combined with c...
Figure S3. Scatter plots demonstrating the correlation between PD-L1 expression on tumor cells and t...
Figure S2. Box plot showing the distribution of TMB between the entire cohort of patients with SCLC ...
Figure S5. Kaplan-Meier analysis of overall survival (OS) calculated from the date of initial pathol...
Figure S6. Kaplan-Meier analysis of progression-free survival (PFS) to first-line chemotherapy in th...
Figure S3. Kaplan-Meier analysis of (A) progression-free survival (PFS) and (B) overall survival (OS...
Figure S1. Diagram of patients with SCLC who underwent successful next generation sequencing who eit...
Table S1. Samples (n=209) sorted within tumor type by PD-L1 rank (RNA-seq). Table S2. PD-L1 (CD274) ...
Figure S1. Comparison of CD8 levels in PD-L1 negative and positive groups. A & B: Comparison of CD8 ...
Table S1. Clinical characteristics. Table S2. RNA-seq gene function list. Table S3. Gene function an...
Table S1. Patientsâ clinical characteristics. Ten newly diagnosed lung cancer patients who were tr...
Figure S2. The consistency of mutation numbers, ITH and phylogenetic trees between panel sequencing ...
Figure S1. Methods, antibodies and validation that IIC-density does not correlate with patient clini...
Figure S1. The correlations of TMB value between panel sequencing and WES in published databases. Fi...
Figure S4. Scatter plot demonstrating the correlation between infiltrating PD-1+ tumor-infiltrating ...
Figure S2. Disease control rates for PD-L1 positive (TPS >â1%) and negative tumors combined with c...
Figure S3. Scatter plots demonstrating the correlation between PD-L1 expression on tumor cells and t...